TY - JOUR
T1 - Ultrasound assessment of postplacental copper intrauterine device position 6 months after placement during cesarean delivery
AU - Gurney, Elizabeth P.
AU - McAllister, Arden
AU - Lang, Britt
AU - Schreiber, Courtney A.
AU - Sonalkar, Sarita
N1 - Funding Information:
Dr. Gurney is a Nexplanon trainer for Merck. Dr. Schreiber is a consultant for Bayer Pharmaceuticals and Athenium Pharmaceuticals and receives research funding from Society of Family Planning, Bayer Pharmaceuticals, Sebela Pharmaceuticals, Medicines360 and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Sonalkar receives research funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Funding Information:
This research was supported by the Society of Family Planning Research Fund ( SFPRF15-15 ). Work on this project was supported in part by a Women's Reproductive Health Research award (S.S., K12-HD001265-18 ) and a Society of Family Planning Research Fund midcareer mentor award (C.A.S., SFPRF11-MC2 ).
Funding Information:
The authors wish to acknowledge the contribution of Jessica McClusky, B.S.N. University of Pennsylvania, Perelman School of Medicine (financial compensation provided by the Society of Family Planning) in conducting this research, and Nidhi Charan, B.S. University of Pennsylvania, Perelman School of Medicine, who created the Table 2 illustrations. This research was supported by the Society of Family Planning Research Fund (SFPRF15-15). Work on this project was supported in part by a Women's Reproductive Health Research award (S.S. K12-HD001265-18) and a Society of Family Planning Research Fund midcareer mentor award (C.A.S. SFPRF11-MC2). Intrauterine devices used in our hospital during this study were donated by Teva Pharmaceuticals, the Ryan LARC Grant and the philanthropic efforts of Dr. Ann Steiner's LARC Project. The funding sources and organizations donating intrauterine devices had no role in study design; data collection, analysis or interpretation; manuscript writing; or the decision to submit for publication. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:, Dr. Gurney is a Nexplanon trainer for Merck. Dr. Schreiber is a consultant for Bayer Pharmaceuticals and Athenium Pharmaceuticals and receives research funding from Society of Family Planning, Bayer Pharmaceuticals, Sebela Pharmaceuticals, Medicines360 and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Sonalkar receives research funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/1
Y1 - 2020/1
N2 - Objective: The objective was to describe the sonographic position of copper intrauterine devices (IUDs) 6 months after insertion during cesarean delivery. Study design: This prospective, observational study followed participants who received a copper IUD during cesarean delivery. We performed pelvic examination at 6 weeks and 6 months and sonography at 6 months to determine IUD position. Patients had additional examinations as needed to address complications. Results: Sixty-nine participants provided outcomes through 6 months: 41 (59%) had correctly positioned IUDs, 21 (30%) had malpositioned intrauterine IUDs, 5 experienced expulsion (3 partial, 2 complete), and 2 had elective removal; 52 (75%) had missing strings. Missing strings at 6 weeks predicted an incorrect IUD position in 22 of 52 participants (positive predictive value 42%), and visible or palpable strings predicted a correct IUD position in 7 of 12 participants (negative predictive value 58%). Conclusion: Although 59% of copper IUDs placed during cesarean were correctly positioned at 6 months, nearly one third were malpositioned. Implications: Ultrasound may be indicated for patients receiving a copper IUD during cesarean delivery as checking IUD strings alone does not assure correct placement. Providers offering postpartum IUDs should ensure that appropriate processes for the evaluation and management of devices with missing strings or abnormal position are available to all patients regardless of insurance status.
AB - Objective: The objective was to describe the sonographic position of copper intrauterine devices (IUDs) 6 months after insertion during cesarean delivery. Study design: This prospective, observational study followed participants who received a copper IUD during cesarean delivery. We performed pelvic examination at 6 weeks and 6 months and sonography at 6 months to determine IUD position. Patients had additional examinations as needed to address complications. Results: Sixty-nine participants provided outcomes through 6 months: 41 (59%) had correctly positioned IUDs, 21 (30%) had malpositioned intrauterine IUDs, 5 experienced expulsion (3 partial, 2 complete), and 2 had elective removal; 52 (75%) had missing strings. Missing strings at 6 weeks predicted an incorrect IUD position in 22 of 52 participants (positive predictive value 42%), and visible or palpable strings predicted a correct IUD position in 7 of 12 participants (negative predictive value 58%). Conclusion: Although 59% of copper IUDs placed during cesarean were correctly positioned at 6 months, nearly one third were malpositioned. Implications: Ultrasound may be indicated for patients receiving a copper IUD during cesarean delivery as checking IUD strings alone does not assure correct placement. Providers offering postpartum IUDs should ensure that appropriate processes for the evaluation and management of devices with missing strings or abnormal position are available to all patients regardless of insurance status.
KW - Copper intrauterine device
KW - Intrauterine device complication
KW - Intrauterine device expulsion
KW - Postpartum contraception
KW - Postpartum intrauterine device
KW - Postplacental intrauterine device
UR - http://www.scopus.com/inward/record.url?scp=85094583150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094583150&partnerID=8YFLogxK
U2 - 10.1016/j.conx.2020.100040
DO - 10.1016/j.conx.2020.100040
M3 - Article
AN - SCOPUS:85094583150
SN - 2590-1516
VL - 2
JO - Contraception: X
JF - Contraception: X
M1 - 100040
ER -